Skip to main content
IKT logo

IKT · Inhibikase Therapeutics, Inc. · Documents

Track IKT — free
$1.32 +0.02 (+1.54%) At close · Nov 20 Q2 2024 earnings call transcript
Market Cap
$185.16M
Shares
140.27M
Volume · Nov 20 1.11M Avg daily vol (3M) 580.26K

The company's filings, earnings calls and investor events, most recent first. Search and read these filings from Claude or ChatGPT with the SEC filings MCP server →

Annual report FY2025 Net loss $48.26M 10-K filed Mar 26, 2026 Quarterly report FY2026 Q3 Net loss $20.47M 10-Q filed Nov 10, 2026 Latest results IMPROVE-PAH gains 28 approvals, activates 79 sites 8-K filed Nov 10, 2026 Earnings call Q2 2024 earnings call Held Jun 30, 2024
2026
Nov 16
Investor event
Safety update 2027, PVR data mid-2028, pivotal mid-2029

Inhibikase's CEO said the phase three program has 28 countries approved and 79 sites running. A safety update is planned for 2027, covering 50 patients and 12 weeks of data, with a PVR readout in mid-2028 and pivotal data in mid-2029. The 2027 update is tied to a $55 million financing.

6 source passages
We have 28 countries approved and 79 sites up and running. So in 2027, what we've communicated is that we will provide what we've called a safety update what we are obligated to do for a financing tranche is to have 50 patients into the study and 12 weeks worth of data. and then a really exciting readout for us is mid-2028. So think of that as sort of mid-2029 is when we said we'd finish the Part B of the study. That brings in a $55 million financing for us Open the document at this passage
Nov 10
Quarterly report 10-Q FY2026 Q3, ended Sep 30
FDA grants orphan designation as Phase 3 trial advances

Inhibikase Therapeutics said the FDA granted orphan drug designation for IKT-001 in July 2026, while Phase 3 IMPROVE-PAH was enrolling across 79 clinical sites; cash, cash equivalents and marketable securities totaled $193.3 million.

Net loss $20.47M Diluted EPS -$0.10
Read from the MD&A section
3 source passages
Following our submission of an Orphan Drug Designation (“ODD”) application to the FDA for IKT-001 for PAH in April 2026, the FDA's Office of Orphan Products Development granted ODD for IKT-001 in July 2026. Our Phase 3 clinical study, named IMPROVE-PAH (IKT-001 for Measuring Pulmonary Vascular Resistance and Outcome Variables in a Phase 3 Evaluation of PAH), which is a single pivotal global study, is presently enrolling patients with 28 country regulatory approvals globally and 79 clinical sites activated to date, and three additional pending country regulatory approvals and one planned country regulatory submission. At September 30, 2026, we had cash, cash equivalents and marketable securities of $193.3 million. Open the document at this passage
Nov 10
Current report 8-K
IMPROVE-PAH gains 28 approvals, activates 79 sites

Inhibikase Therapeutics reported 28 country regulatory approvals and 79 activated clinical sites for IMPROVE-PAH. Cash, cash equivalents and marketable securities totaled $193.3 million, while quarter-ended net loss was $20.5 million, or $0.10 per share.

Financial results
3 source passages
“During our third quarter and in recent weeks we continued to advance our Phase 3 IMPROVE-PAH study, for which we have obtained 28 country regulatory approvals in the U.S. and E.U., with 79 clinical sites activated across a range of countries,” said Mark Iwicki, Chief Executive Officer of Inhibikase. Cash Position: As of September 30, 2026, cash, cash equivalents and marketable securities were $193.3 million. Net Loss: Net loss for the quarter ended September 30, 2026, was $20.5 million, or $0.10 per share, compared to a net loss of $11.9 million, or $0.13 per share in the quarter ended September 30, 2025. Open the document at this passage
Oct 20
Current report 8-K Events of Oct 19
Scott Wasserman joins board after Dennis Berman resigns

Inhibikase Therapeutics said Dennis Berman resigned from its board and committee roles effective October 19, 2026. The board appointed Scott Wasserman as a Class III director the same day, with options to purchase up to 310,000 shares.

Director or officer change, or executive pay, Regulation FD disclosure
4 source passages
Dennis Berman resigned from the board of directors effective as of October 19, 2026 appointed Scott Wasserman to serve as a Class III director non-qualified stock options to purchase up to 310,000 shares Open the document at this passage
Aug 11
Quarterly report 10-Q FY2026 Q2, ended Jun 30
Quarterly report for FY2026 Q2 AI summary on its way
Revenue $0 Net loss $19.59M Diluted EPS -$0.11
Jul 14
Current report 8-K
Other events AI summary on its way
May 12
Quarterly report 10-Q FY2026 Q1, ended Mar 31
Quarterly report for FY2026 Q1 AI summary on its way
Revenue $0 Net loss $16.38M Diluted EPS -$0.10
Apr 30
Proxy statement DEF 14A Meeting Jun 26, 2026
Proxy statement AI summary on its way
Apr 20
Proxy statement PRE 14A Meeting Jun 26, 2026
Proxy statement AI summary on its way
Mar 26
Annual report 10-K FY2025, ended Dec 31
Annual report for FY2025 AI summary on its way
Net loss $48.26M Diluted EPS -$0.49
2025
Mar 27
Annual report 10-K FY2024, ended Dec 31
Annual report for FY2024
Revenue $0 Net loss $27.52M Diluted EPS -$1.16
2024
Showing 1–50 of 156 documents
Key facts CIK 1750149 CUSIP 45719W205 13F (30d) 109 filings 103 filers Visit website Investor relations